Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PH for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years; in other countries, forecasts cover 10 years. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.
Clarivate Epidemiology’s PH forecast will answer the following questions:
All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least 10 years of forecast data for the following PH patient populations:
… and many more (details available on request).
Note: Coverage may vary by country and region.